Barriers to HAART adherence among human immunodeficiency virus - Infected adolescents

Archives of Pediatrics and Adolescent Medicine

Volumn 157, Issue 3, 2003, Pages 249-255

  Murphy, Debra A ^a   Sarr, Moussa ^b   Durako, Stephen J ^b   Moscicki, Anna Barbara ^c   Wilson, Craig M ^d   Muenz, Larry R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTAT   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; FACTORIAL ANALYSIS; FEMALE; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRESCRIPTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SELF REPORT; SEXUAL BEHAVIOR; UNITED STATES; VIRUS LOAD;

EID: 0037345510     PISSN: 10724710     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpedi.157.3.249     Document Type: Article

References (43)

1. Centers for Disease Control Prevention. HIV AIDS Surveill Rep. 2000;12(1):15.
2. Ellen JM. Adolescents and HIV Potomac Falls, Va: The Johns Hopkins University AIDS Service; 2002. The Hopkins HIV Report. 2000;14(No. 3):10-12.
3. Ellen JM. Adolescents and HIV Potomac Falls, Va: The Johns Hopkins University AIDS Service; 2002. The Hopkins HIV Report. 2000;14(No. 3):10-12.
4. Sweeney P, Lindegren ML, Buehler JW, Onorato IM, Janssen RS. Teenagers at risk of human immunodeficiency virus type 1 infection: results from seroprevalence surveys in the United States. Arch Pediatr Adolesc Med. 1995;149:521-528.
5. Valleroy LA, MacKellar DA, Karon JM, Janssen RS, Hayman CR. HIV infection in disadvantaged out-of-school youth: prevalence for U.S Job Corps entrants, 1990 through 1996. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:67-73.
6. Pfeifer RW, Oliver J. A study of HIV seroprevalence in a group of homeless youth in Hollywood, California. J Adolesc Health. 1997;20:339-342.
7. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 2002;30:105-110.
8. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
9. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
10. Murphy DA, Roberts KJ, Martin DJ, Marelich W, Hoffman, D. Barriers to antiretroviral adherence among HIV-infected adults. AIDS Patient Care STDS. 2000;14:47-58.
11. Montaner JS, Reiss P, Cooper D, et al, forthe INCAS (Italy, the Netherlands, Canada, and Australia Study). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA. 1998;279:930-937.
12. Paterson D, Swindells S, Mohr J, et al. How much adherence is enough? a prospective study of adherence to protease inhibitor therapy using MEMS Caps. Paper presented at: Sixth Conference on Retroviruses and Opportunistic Infections; February 1, 1999; Chicago, Ill.
13. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci U S A. 2001;98:15161-15166.
14. Ho DD, Neuman AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
15. Perelson AS, Neuman AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996;271:1582-1586.
16. Friedland GH. Adherence: the Achilles' heel of highly active antiretroviral therapy. In: Improving the Management of HIV Disease. San Francisco, Calif: International AIDS Society-USA; 1997:13-15.
17. Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
18. Freeman TL, Steward KE, DeMasi R, Saag MS. Adherence in the age of highly active anti-retroviral therapy (HAART): racial and gender differences. Paper presented at: National HIV Prevention Conference; August 29-September 1, 1999; Atlanta, Ga.
19. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? a novel assessment technique. JAMA. 1989;261:3273-3277.
20. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: a neglected issue. AIDS Educ Prev. 1996;8:58-71.
21. Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus type I: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92:495-502.
22. Mostashari F, Riley E, Selwyn PA, Altice FL. Acceptance and adherence with antiretroviral therapy among HIV-infected women in a correctional facility. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:341-348.
23. Murphy DA, Roberts KJ, Hoffman D, Molina A, Lu MC. Barriers and successful strategies to antiretroviral adherence among HIV-infected monolingual Spanish-speaking patients. AIDS Care. In press.
24. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort. AIDS Care. 2001;13:27-40.
25. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316-319.
26. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health. 1998;22:300-311.
27. + T cell counts and HIV type 1 viral loads in untreated, infected adolescents. AIDS Res Hum Retroviruses. 2000;16:959-963.
28. Chesney MA, Folkman S. Psychological impact of HIV disease and implications for intervention. Psychiatr Clin North Am. 1994;17:163-182.
29. Chesney MA, Ickovics JR, Chambers DB, et al, for the Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12:255-266.
30. Harman HH. Modern Factor Analysis. 2nd ed. Chicago, Ill: University of Chicago Press; 1967.
31. SAS Institute. SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute Inc; 1999:1123-1192.
32. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB, for the Adolescent Medicine HIV/AIDS Research Network. The REACH (Reaching for Excellence in Adolescent Care and Health) Project: study design, methods, and population profile. J Adolesc Health. 2001;29(suppl 3):8-18.
33. Balestra P, Ferri F, Galgani S, et al. Clinical, psychological, and behavioral characteristics of HIV patients reporting low compliance to treatments. Paper presented at: International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia.
34. Chow R, Chin T, Fong IW, Bendayan R. Medication use patterns in HIV-positive patients. Can J Hosp Pharm. 1993;46:171-175.
35. Singh N, Squier C, Sivek C, Wagener M, Nguyen MH, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261-269.
36. Litt IF. Know thyself-adolescents' self-assessment of compliance behavior. Pediatrics. 1985;75:693-696.
37. Kleiger JH, Dirks JF. Medication compliance in chronic asthmatic patients. J Asthma Res. 1979;16:93-96.
38. Tamaroff MH, Festa RS, Adesman AR, Walco GA. Therapeutic adherence to oral medication regimens by adolescents with cancer, II: clinical and psychologic correlates. J Pediatr. 1992;120:812-817.
39. Tebbi CK. Treatment compliance in childhood and adolescence. Cancer. 1993;71:3441-3449.
40. Murphy DA, Durako S, Muenz LR, Wilson CM. Marijuana use among HIV-positive and high-risk adolescents: a comparison of self-report through audio computer-assisted self-administered interviewing and urinalysis. Am J Epidemiol. 2000;152:805-813.
41. Lemanek KL, Kamps J, Chung NB. Empirically supported treatments in pediatric psychology: regimen adherence. J Pediatr Psychol. 2001;26:253-275.
42. Méndez, FJ, Beléndez M. Effects of a behavioral intervention on treatment adherence and stress management in adolescents with IDDM. Diabetes Care. 1997;20:1370-1375.
43. Misuraca A, Di Gennaro M, Lioniello M, Duval M, Aloi G. Summer camps for diabetic children: an experience in Campania, Italy. Diabetes Res Clin Pract. 1996;32:91-96.